Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21421673 | 0.86 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL21673387 | 0.85 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21673754 | 0.79 | — | — | |
| SCHEMBL25600523 | 0.78 | KDM1A (0.38) | SLC6A2SLC6A4SLC6A3POLB | |
| SCHEMBL23204659 | 0.77 | OPRM1 (0.31) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL23205742 | 0.77 | OPRM1 (0.31) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL21673391 | 0.76 | SLC6A3 (0.34) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL29316815 | 0.75 | HRH3 (0.37) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL23204666 | 0.74 | HTR2A (0.32) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL23204660 | 0.74 | HTR2A (0.32) | HTR2AHTR2CHTR2BSIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | SLC6A2 4294/4885SLC6A4 4476/4885SLC6A3 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.